Table 2.

Compounds with demonstrable effectiveness against metabolic conditions in preclinical testing

Compound	Target	Effects	References
CNIO-PI3Ki	PI3K	Anti-obesity	Ortega-Molina et al. (2015)
Metformin	AMPK and other targets	Improved insulin sensitivity and plasma lipid profiles	Martin-Montalvo et al. (2013)
Rapamycin	mTOR	Reduced body weight, enhanced insulin sensitivity	Fang et al. (2013)
SIRT1720	Allosteric SIRT1 activator	Lower body weight Improved glucose tolerance and insulin sensitivity	Mitchell et al. (2014)

List of compounds with activity on metabolic signalling pathways shown to be well tolerated and to induce beneficial metabolic effects upon chronic administration in mammalian models